Cargando…

Zanubrutinib-induced liver injury: a case report and literature review

BACKGROUND: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atallah, Edmond, Wijayasiri, Pramudi, Cianci, Nicole, Abdullah, Khorrum, Mukherjee, Abhik, Aithal, Guruprasad P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164809/ https://www.ncbi.nlm.nih.gov/pubmed/34051727 http://dx.doi.org/10.1186/s12876-021-01825-2

Ejemplares similares

Estimating the clinical prevalence of Wilson’s disease in the UK
por: Wijayasiri, Pramudi, et al.
Publicado: (2021)

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review
por: Niu, Hao, et al.
Publicado: (2022)

Zanubrutinib-induced aseptic meningitis: a case report and literature review
por: Yang, Jinjun, et al.
Publicado: (2023)

Role of Hepatocyte Senescence in the Activation of Hepatic Stellate Cells and Liver Fibrosis Progression
por: Wijayasiri, Pramudi, et al.
Publicado: (2022)

Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
por: Cianci, Nicole, et al.
Publicado: (2022)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study
por: Atallah, Edmond, et al.
Publicado: (2023)

Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review
por: Wang, Lingling, et al.
Publicado: (2022)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Drug-induced liver injury: recent advances in diagnosis and risk assessment
por: Kullak-Ublick, Gerd A, et al.
Publicado: (2017)

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
por: Maggioni, Giuseppe, et al.
Publicado: (2023)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Bilateral Cystoid Macular Edema with Zanubrutinib Therapy: A Case Report
por: Pennipede, Dante, et al.
Publicado: (2023)

Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
por: Li, Wenqi, et al.
Publicado: (2023)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
por: Alsuhebany, Nada, et al.
Publicado: (2023)

Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review
por: Xing, Lijie, et al.
Publicado: (2021)

Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury
por: Gai, Zhibo, et al.
Publicado: (2023)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Disseminated fungal infection in a patient receiving zanubrutinib
por: Walsh, Madalyn, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal
por: Tang, Peng-fei, et al.
Publicado: (2023)

Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy
por: Thiagarajan, Prarthana, et al.
Publicado: (2021)

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib
por: Zhang, Xiao, et al.
Publicado: (2022)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
por: Wang, Liang, et al.
Publicado: (2021)

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
por: Lynes, John, et al.
Publicado: (2022)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Biomarkers in Liver Disease: Emerging Methods and Potential Applications
por: Aithal, Guruprasad P., et al.
Publicado: (2012)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ct8cgbhju2sauqj1k8gtn4gnnp